Status:
COMPLETED
Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Collaborating Sponsors:
Sichuan Cancer Hospital and Research Institute
Henan Cancer Hospital
Conditions:
Metastatic Esophageal Squamous Cell Carcinoma
Eligibility:
All Genders
18-90 years
Brief Summary
This study is a multi-center, non-interventional study. Clinicopathologic, treatment , outcome and efficacy data will be collected from medical records in metastatic esophageal squamous cell carcinoma...
Detailed Description
This study is a multi-center, non-interventional study. Patients' background, treatment pattern, treatment outcome, efficacy will be collected in metastatic esophageal squamous cell carcinoma (ESCC) p...
Eligibility Criteria
Inclusion
- Pathologically diagnosed as esophageal squamous cell carcinoma;
- The clinical stage is IVb stage, that is, non-regional lymph node metastasis and distant organ metastasis (AJCC8th) of esophageal carcinoma.
- Patients had received no previous systemic therapy
- Patients who had received at least one cycle of first-line chemotherapy combined with immunotherapy, received or did not receive radiotherapy;
- Complete medical records;
- ECOG0-2;
Exclusion
- Surgery for esophageal cancer;
- Esophageal fistulae due to infiltration of the primary tumour.
- Risk of gastrointestinal bleeding, oesophageal fistula or oesophageal perforation
- Those who have a history of autoimmune disease or have been treated with immunosuppressants within the last 3 months.
- Those who have received organ transplant surgery.
- Patients with a previous history of malignant tumor (skin basal cell carcinoma and cervical carcinoma in situ) survived tumor-free for 3 years after treatment.
- Except for the above).
- There are other serious diseases, such as myocardial infarction, cerebral infarction or severe cardiopulmonary insufficiency within 6 months
Key Trial Info
Start Date :
October 13 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 4 2023
Estimated Enrollment :
728 Patients enrolled
Trial Details
Trial ID
NCT06190652
Start Date
October 13 2018
End Date
December 4 2023
Last Update
February 5 2024
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Henan Cancer Hospital
Zhengzhou, Henan, China
2
Hunan Cancer Hospital
Changsha, Hunan, China
3
Shanxi Cancer Hospital
Taiyuan, Shanxi, China
4
Sichuan Cancer Hospital
Chengdu, Sichuan, China